glp 1 agonists oral Orforglipron, an Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes Five Unexpected New Uses for

As more GLP-1 prescriptions are written to manage not just diabetes and cardiovascular disease but also obesity, a key question emerges: What is the role of patient engagement and chronic disease management when prescribing these drugs

It will be interesting to see where healthcare organizations land on some of these questions, since many are in the unique position of both sponsoring health coverage and providing actual care to their employees

J Cell Biol (2018) 217(2):45972

Amycretin is Novo Nordisks GLP-1 and amylin receptor agonist, being developed in both injectable and oral forms

[DOI] [PubMed] [Google Scholar] 91

June 2025: The European Medicines Agencys (EMAs) safety committee concluded that NAION is a very rare potential side effect of semaglutide medicines, like Wegovy